Drug Trial Radar · NCT07326540
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
248
Planned (sponsor's estimate)
Start
Mar 27, 2026
Primary completion
Dec 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- BioVersys SASIndustry
- Sponsor type
- Industry
- Collaborators
- BioVersys AG
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 82 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). Part B is the single-group portion of the study and includes patients with HABP or VABP with CRABC infections that are resistant to or have failed colistin/polymyxin B treatment.
Conditions
- Hospital Acquired Bacterial Pneumonia (HABP)
- Ventilator Associated Bacterial Pneumonia (VABP)
- Colistin Resistanrt ABC
- Acinetobacter Baumannii-calcoaceticus Complex
Interventions
BV100 (300 mg)Drug
300 mg BV100 nfused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.
Polymyxin BDrug
50 mg polymyxin B infused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.
ColistinDrug
Colistin (4,500,000 units infused over 1 hour every 12 hours (q12h), after an initial loading dose of 9,000,000 units infused over 1 hour).Treatment for 7 days up to 14 days if clinically indicated.
Ampicillin-SulbactamDrug
High dose ampicillin/sulbactam (6 g/3 g IV over 4 hours q8h).Treatment for 7 days up to 14 days if clinically indicated.
MEROPENEM 2 grams TIDDrug
meropenem infused over 1 hour every 8 hours (q8h).Treatment for 7 days up to 14 days if clinically indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with All-Cause Mortality in CRABC m-MITT PopulationTime frame: Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital
Tbilisi, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.